Actelion: BREATHE to BUILD growth

Actelion Ltd.'s near term growth rests in the hands of its development and marketing teams. With one home-grown and one in-licensed product on the market, the company plans to spend the next few years maximizing sales of Tracleer bosentan and Zavesca miglustat.

Tracleer is marketed to treat pulmonary arterial hypertension (PAH) and Zavesca to treat Gaucher's disease. Where other companies might focus on in-licensing compounds or expediting early stage clinical development programs, ATLN is looking to expand indications for both drugs. If successful, the increased income would enable ATLN to circle back around and build a bigger pipeline. ...